GENFIT DISTINGUISHED AWARDS FOR INVESTOR `2014` ORGANIZED BY BOURSORAMA AND MORNINGSTAR Lille (France), Boston (Massachusetts, USA), November 28, 2014 - GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company engaged in the discovery and development of therapeutic and diagnostic solutions in the field of metabolic diseases and inflammatory, such as corporate hepato-gastroenterology sphere, announced it has been distinguished with INVESTOR AWARDS 2014 in the category “Young Talent”.
GENFIT was considered favorite company`s excluding CAC 40, which was listed for less than 10 years across all criteria. This award resulting d`un vote submitted between 28 August and 2 November to users of Boursorama and Morningstar, both professional and personal Putting all management companies authorized in France.
Jean-François Mouney, CEO of GENFIT declared : “This distinction rewards our communication efforts and d`information l`ensemble to our shareholders. Let them be individual shareholders or representatives of the most prestigious financial institutions, we attach great d`importance to inform all with the same care. This communication policy is a way for us to share our enthusiasm with them to discover and develop innovative medicines for little or unmet medical needs. Do you even lift
About GENFIT:
GENFIT is a biopharmaceutical company dedicated to the discovery and development of drugs in therapeutic areas where medical needs are high due to the lack of effective treatments and because of l`augmentation the number of patients globally .dropoff window GENFIT focuses its R & D efforts to participate in the marketing of therapeutic solutions to combat certain metabolic, inflammatory, autoimmune or fibrotic particularly affecting the liver (such as non-alcoholic steatohepatitis or NASH) or bowel (such as chronic inflammatory bowel disease). GENFIT deploys combined approaches involving new therapies and biomarkers, and disposes of a portfolio of drug candidates whose GFT505, proprietary compound GENFIT the most advanced, currently completing a Phase 2b in NASH.
With facilities in Lille and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the regulated market of Euronext in Paris, compartment B (Euronext: GNFT; ISIN: FR0004163111). www.genfit.fr
Contact
GENFIT | Jean-François Mouney - Chief Executive Officer | Tel. +333 2016 4000
Help employers find you! Check out all the jobs and post your resume.
